152 related articles for article (PubMed ID: 2885168)
1. Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Benfield P; Sorkin EM
Drugs; 1987 Apr; 33(4):392-412. PubMed ID: 2885168
[TBL] [Abstract][Full Text] [Related]
2. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
Wiest D
Clin Pharmacokinet; 1995 Mar; 28(3):190-202. PubMed ID: 7758250
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics and therapeutic efficacy of esmolol.
Wiest DB; Haney JS
Clin Pharmacokinet; 2012 Jun; 51(6):347-56. PubMed ID: 22515557
[TBL] [Abstract][Full Text] [Related]
4. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
Angaran DM; Schultz NJ; Tschida VH
Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
[TBL] [Abstract][Full Text] [Related]
5. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R
Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341
[TBL] [Abstract][Full Text] [Related]
6. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
Barbier GH; Shettigar UR; Appunn DO
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
[TBL] [Abstract][Full Text] [Related]
7. Esmolol: a novel cardioselective, titratable, intravenous beta-blocker with ultrashort half-life.
Covinsky JO
Drug Intell Clin Pharm; 1987 Apr; 21(4):316-21. PubMed ID: 2882993
[TBL] [Abstract][Full Text] [Related]
8. [Esmolol in anesthesiology: pharmacology and indications].
Fita G; Gomar C; Rovira I
Rev Esp Anestesiol Reanim; 1999 Nov; 46(9):404-14. PubMed ID: 10613078
[TBL] [Abstract][Full Text] [Related]
9. Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension.
Garnock-Jones KP
Drugs; 2012 Jan; 72(1):109-32. PubMed ID: 22191799
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
Anderson S; Blanski L; Byrd RC; Das G; Engler R; Laddu A; Lee R; Rajfer S; Schroeder J; Steck JD
Am Heart J; 1986 Jan; 111(1):42-8. PubMed ID: 2868645
[TBL] [Abstract][Full Text] [Related]
11. Esmolol, the first ultra-short-acting intravenous beta blocker for use in critically ill patients.
Blanski L; Lutz J; Laddu A
Heart Lung; 1988 Jan; 17(1):80-9. PubMed ID: 3276651
[TBL] [Abstract][Full Text] [Related]
12. [New ultra-short-acting beta-blockers: landiolol and esmolol--the effects on cardiovascular system].
Mio Y
Masui; 2006 Jul; 55(7):841-8. PubMed ID: 16856544
[TBL] [Abstract][Full Text] [Related]
13. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.
Gray RJ
Chest; 1988 Feb; 93(2):398-403. PubMed ID: 2892647
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of esmolol in the treatment and transfer of patients with supraventricular tachyarrhythmias to alternate oral antiarrhythmic agents.
Das G; Tschida V; Gray R; Dhurandhar R; Lester R; McGrew F; Askenazi J; Kaplan K; Emanuele M; Turlapaty P
J Clin Pharmacol; 1988 Aug; 28(8):746-50. PubMed ID: 2905710
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial.
Abrams J; Allen J; Allin D; Anderson J; Anderson S; Blanski L; Chadda K; DiBianco R; Favrot L; Gonzalez J
Am Heart J; 1985 Nov; 110(5):913-22. PubMed ID: 3904379
[TBL] [Abstract][Full Text] [Related]
16. Controlled beta-receptor blockade with esmolol and flestolol.
Murthy VS; Frishman WH
Pharmacotherapy; 1988; 8(3):168-82. PubMed ID: 2902602
[TBL] [Abstract][Full Text] [Related]
17. Esmolol and the adrenergic response to perioperative stimuli.
Murthy VS; Hwang TF; Sandage BW; Laddu AR
J Clin Pharmacol; 1986 Mar; 26(S1):A27-A35. PubMed ID: 2870083
[TBL] [Abstract][Full Text] [Related]
18. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.
Mooss AN; Hilleman DE; Mohiuddin SM; Hunter CB
Ann Pharmacother; 1994 Jun; 28(6):701-3. PubMed ID: 7919552
[TBL] [Abstract][Full Text] [Related]
19. [Esmolol--beta-adrenergic blocking agent with ultrashort action].
Marenović T; Stojiljković MP; Marković M
Srp Arh Celok Lek; 1992 Jun; 120 Suppl 4():65-70. PubMed ID: 18193815
[TBL] [Abstract][Full Text] [Related]
20. Interactions of esmolol and adenosine in atrioventricular nodal-dependent supraventricular tachycardia: implication for the cellular mechanisms of adenosine.
Chang KC; Lin YC; Chen JY; Chou HT; Hung JS
Cardiology; 2002; 97(3):138-46. PubMed ID: 12077566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
